ライフサイエンスコーパス: antifibrinolytic

1 t of treatment delay on the effectiveness of antifibrinolytics.

2 use factor XI displays both procoagulant and antifibrinolytic activities, it has been postulated that

3 Reverse zymography showed no antifibrinolytic activity in these zones.

4 teric inhibition of plasmin could led to new antifibrinolytic agent(s) that may exhibit better effica

5 ared with the use of aminocaproic acid or no antifibrinolytic agent, aprotinin use was also associate

6 d to delay clot lysis by enhancing a natural antifibrinolytic agent, thrombin-activatable fibrinolysi

7 herefore, it has been proposed for use as an antifibrinolytic agent.

8 n those who received aminocaproic acid or no antifibrinolytic agent.

9 Because the 2 antifibrinolytic agents appear to have similar efficacie

10 or tranexamic acid, which have been used as antifibrinolytic agents to prevent blood loss during maj

11 The use of the antifibrinolytic agents urokinase and recombinant tissue

12 All antifibrinolytic agents were effective in reducing blood

13 ich are representative of a class of in vivo antifibrinolytic agents, have been determined at 2.1 ang

14 nephrotoxic insults are presented, including antifibrinolytic agents, obstructive jaundice, prostagla

15 surgery according to use of 2 lysine analog antifibrinolytics (aminocaproic acid and tranexamic acid

16 on, thereby preventing the generation of the antifibrinolytic and anti-inflammatory activities of TAF

17 Antifibrinolytics and heparinase partially reverse the a

18 ric clotting patterns, which was reversed by antifibrinolytics and heparinase.

19 Pharmacologic agents including antifibrinolytics and prohemostatic proteins are commonl

20 In addition, the use of medications, such as antifibrinolytics, and point of care testing, such as th

21 However, recent studies suggest that the antifibrinolytic aprotinin is associated with increased

22 Antifibrinolytics are used to attenuate the coagulopathy

23 Thus, the anticoagulant and antifibrinolytic cofactor activities of thrombomodulin h

24 ty is a hallmark of new thrombi and that the antifibrinolytic cross-linking effects of FXIIIa are ach

25 The most commonly used antifibrinolytic drug, tranexamic acid, is associated wi

26 Antifibrinolytic drugs are routinely used worldwide to r

27 Antifibrinolytic drugs are widely used to reduce blood l

28 e plasmin is a target for the development of antifibrinolytic drugs for use in cardiac surgery with c

29 l lead structures for the development of new antifibrinolytic drugs for use in cardiac surgery with c

30 rporeal circulation; however, the effects of antifibrinolytic drugs on proinflammatory and anti-infla

31 Antifibrinolytic drugs such as aprotinin and epsilon-ami

32 The antifibrinolytic drugs tranexamic acid (TXA) and epsilon

33 suited for further development as injectable antifibrinolytic drugs.

34 eutics that improve upon currently available antifibrinolytics, e.g., tranexamic acid (TXA, 1) and ap

35 se B (PCB) is an exopeptidase that exerts an antifibrinolytic effect by releasing C-terminal Lys and

36 The antifibrinolytic effect of HUVECs was abolished 66% by s

37 In addition, the antifibrinolytic effect of TM was negated by monoclonal

38 y its content of oxidized phospholipids, and antifibrinolytic effects.

39 of Lp(a) within the blood vessel promotes an antifibrinolytic environment, foam cell formation, the g

40 Empiric antifibrinolytics for children should be questioned; thr

41 activated platelet membrane where it exerts antifibrinolytic function by cross-linking alpha2AP to f

42 Our data show that the antifibrinolytic function of FXIII is independent of fib

43 operties of TFPI-2 or KD1 would diminish its antifibrinolytic function.

44 diated inhibition of TAFI activation and the antifibrinolytic functions of TAFIa.

45 cohort studies: Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) tr

46 e with more than 1000 patients that assessed antifibrinolytics in acute severe bleeding.

47 y, epsilon-aminocaproic acid, an alternative antifibrinolytic, is considerably less expensive.

48 Alterations in circulating prothrombotic or antifibrinolytic mediators in the "fluid phase" of the b

49 Impact of cardiotomy suction and antifibrinolytics on markers of brain injury was assesse

50 utics targeting major thrombin-generating or antifibrinolytic pathways may disrupt fibrin-mediated ho

51 a significant inhibition of procoagulant and antifibrinolytic pathways.

52 In conclusion, the antifibrinolytic properties of Solulin are exhibited in

53 ave established important antithrombotic and antifibrinolytic properties of this serpin that have her

54 and monocyte chemotactic protein-1, and the antifibrinolytic protein plasminogen activator inhibitor

55 evels of fibrinogen, protein C activity, and antifibrinolytic proteins and deposition of fibrin in ti

56 Antifibrinolytics reduce death from bleeding in trauma a

57 Transexamic acid (TXA) is an antifibrinolytic that has been used successfully to prev

58 Since the 1980s, antifibrinolytic therapies have assisted surgical teams

59 or the comparison with patients receiving no antifibrinolytic therapy (P=0.003) and 1.27 (95% CI, 1.1

60 ine protease inhibitor, here we use the term antifibrinolytic therapy to include all three agents.) R

61 r ST-elevation myocardial infarction receive antifibrinolytic therapy to limit blood loss.

62 acid, and 2029 patients (20.0%) received no antifibrinolytic therapy.

63 receiving aprotinin, tranexamic acid, or no antifibrinolytic treatment in the presence or absence of

64 To develop a recommendation for antifibrinolytic use in adult cardiac surgery, we perfor

65 Antifibrinolytic use was documented.

66 analysis to determine the association of the antifibrinolytics with efficacy, safety and cost outcome